Nereus Raises $45 Million

Nereus Pharmaceuticals Inc., a San Diego-based cancer drug company that uses marine microbial sources, has raised $45 million in Series D-2 funding. BankInvest Biomedical Venture of Copenhagen led the deal, and was joined by fellow new backers Roche Venture Fund, Astellas Venture Management, Boston Life Science Venture Corporation, Taiwan Global Biofund and Eminent Venture Capital Corp. Returning shareholders included HBM BioVentures, Alta Partners, Forward Ventures, Advent International, GIMV, InterWest Partners and Pacific Venture Group. Nereus previously raised a $42.6 million Series D-1 round, and has now raised over $127 million in total VC funding since 1998. www.nereuspharm.com